Role of biological therapies targeting eosinophils in eosinophilic granulomatosis with polyangiitis: current evidence and future perspectives
Overall, anti-L-5 therapies represent an effective and safe option for EGPA. Future research should focus on larger, multicenter trials to clarify the pathophysiology of the disease and facilitate the identification of predictive biomarkers, leading for personalized therapeutic strategies.
Authors
- Sara Otero-Torres
- M Calvín-Lamas (ORCID: https://orcid.org/0000-0003-3209-8252)
- Maria Nélida Fernández-Martínez
- Luis Margusino-Framiñán
- Rosa Rodríguez-Mauriz
Institutions
- Duran i Reynals Hospital (ES)
- Instituto de Investigación Biomédica de A Coruña (ES)
- Universidad de León (ES)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/03007995.2026.2629098
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00